Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1001/jamaoncol.2024.3131 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Phase 1 Trial of Image Guided Risk Volume-Adapted Postprostatectomy Radiation Therapy.
Int J Radiat Oncol Biol Phys
October 2024
Radiation Oncology Branch, National Cancer Institute, National Institutes fo Health, Bethesda, Maryland. Electronic address:
Purpose: This was a phase 1 trial with the primary objective of identifying the most compressed dose schedule (DS) tolerable using risk volume-adapted, hypofractionated, postoperative radiation therapy (PORT) for biochemically recurrent prostate cancer. Secondary endpoints included biochemical progression-free survival and quality of life (QOL).
Methods And Materials: Patients were treated with 1 of 3 isoeffective DSs (DS1: 20 fractions, DS2: 15 fractions, and DS3: 10 fractions) that escalated the dose to the imaging-defined local recurrence (73 Gy equivalent dose in 2Gy fractions) and de-escalated the dose to the remainder of the prostate bed (48 Gy equivalent dose in 2Gy fractions).
Hypofractionated Postprostatectomy Radiotherapy-Less is Really More?
JAMA Oncol
August 2024
Department of Radiotherapy, Bergonie Institute, Bordeaux, France.
Stereotactic Radiation Therapy for Kidney Cancer, Hypofractionated Postprostatectomy Radiation, Nasopharyngeal Carcinoma Treatment De-Intensification, Stereotactic Radiation Therapy and Interstitial Lung Disease, and Hyperbaric Oxygen Therapy.
Pract Radiat Oncol
June 2024
Department of Radiation Oncology, Anderson Regional Health System, Meridian, Mississippi. Electronic address:
Overview of Radiation Therapy in the Management of Localized and Metastatic Prostate Cancer.
Curr Urol Rep
August 2024
Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, 195 Little Albany Street, New Brunswick, NJ, 08901, USA.
Purpose Of Review: The goal is to describe the evolution of radiation therapy (RT) utilization in the management of localized and metastatic prostate cancer.
Recent Findings: Long term data for a variety of hypofractionated definitive RT dose-fractionation schemes has matured, allowing patients and providers many standard-of-care options to choose from. Post-prostatectomy, adjuvant RT has largely been replaced by an early salvage approach.
Importance: No prior trial has compared hypofractionated postprostatectomy radiotherapy (HYPORT) to conventionally fractionated postprostatectomy (COPORT) in patients primarily treated with prostatectomy.
Objective: To determine if HYPORT is noninferior to COPORT for patient-reported genitourinary (GU) and gastrointestinal (GI) symptoms at 2 years.
Design, Setting, And Participants: In this phase 3 randomized clinical trial, patients with a detectable prostate-specific antigen (PSA; ≥0.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!